Intech Investment Management Adds $8M in Abbott Laboratories ($ABT)
Intech Investment Management significantly expanded its position in Abbott Laboratories, nearly doubling its shares.
Key Points
- Intech Investment Management boosted its stake in Abbott Laboratories by 93.99%, adding 87,218 shares to total 180,014 shares worth $15.86 million.
- Abbott Laboratories, traded on the NYSE under ABT, has a market cap of $153.59 billion and a P/E ratio of 24.7, with shares trading near $88.12.
- Recent insider buying at Abbott Laboratories included purchases by multiple executives, while analysts maintain a 'buy' consensus with price targets ranging from $115 to $143.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Intech Investment Management has significantly increased its position in Abbott Laboratories (NYSE: ABT). According to the latest 13F filing with the SEC, the firm boosted its holdings by 93.99%, adding 87,218 shares. This brings Intech's total to 180,014 shares, valued at approximately $15.86 million as of the reporting period.
What Changed in Intech Investment Management's Abbott Laboratories Position
Intech Investment Management nearly doubled its stake in Abbott Laboratories during the latest quarter. The firm previously held 92,796 shares and increased this to 180,014 shares, reflecting a substantial addition of 87,218 shares. This move represents a 93.99% increase in their holdings, showcasing increased confidence in the company.
Other Institutional Activity in Abbott Laboratories
Other major institutional investors also made notable moves in Abbott Laboratories. BlackRock, Inc. reduced its position by 1,221,310 shares, ending with 145,687,458 shares valued at about $14.96 billion. Vanguard Capital Management LLC initiated its position with 112,949,933 shares worth approximately $11.60 billion. State Street Corp trimmed its holdings by 278,314 shares, leaving it with 79,575,468 shares valued at $8.17 billion. Meanwhile, Capital Research Global Investors added 10,606,123 shares to hold a total of 49,775,362 shares, valued at $5.11 billion.
Abbott Laboratories Stock Down 19.2%
Shares of Abbott Laboratories (NYSE: ABT) recently traded near $88.12. The company boasts a market cap of $153.59 billion and a P/E ratio of 24.7, with a forward P/E of 14.55. The stock's 52-week range is between $81.97 and $139.06, with a 50-day moving average of $91.22 and a 200-day moving average of $114.49. Abbott has a beta of 0.62, indicating lower volatility compared to the market.
$ABT stock price
Daily closing prices, year to date. Not investment advice.
Recent Earnings
Abbott Laboratories reported revenue of $45.13 billion, with a growth rate of 7.8%. The company achieved a net margin of 13.9% and a return on equity of 12.33%. Its earnings per share stood at $3.57. The next earnings report is expected on April 16, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
8 target cuts vs 0 raises.
-
EPS & revenue
EPS met estimates. Revenue beat estimates by 0.5%.
-
Profit surprise
EBITDA missed by 43 percent. Operating income missed by 19 percent.
-
Pre-earnings setup
Bar was high, analysts already very bullish.
-
Analyst signal
8 target cuts.
-
Earnings quality
Gross margin up 3.7 points. Positive free cash flow.
Earnings Call Summary
Abbott completed its $2.4 billion acquisition of Exact Sciences on March 23 and is integrating the cancer diagnostics business into its portfolio. First quarter results came in slightly ahead, with sales of $11.2 billion, up 3.7 percent on a comparable basis, though the respiratory season was weaker than expected. The company is seeing early signs of volume recovery in Nutrition after price increases, expects Core Lab Diagnostics to accelerate, and is launching new cardiac devices like the Volt pulsed field ablation catheter and TactiFlex Duo. Management remains confident in second half acceleration but is being cautious on near term market conditions.
Guidance Abbott cut full year earnings guidance from $5.68 to $5.48 per share, reflecting $0.20 of dilution from the Exact Sciences acquisition. The company guided full year revenue growth of 6.5 percent to 7.5 percent on a comparable basis including Exact Sciences. For the second quarter, Abbott expects earnings of $1.25 to $1.31 per share. Management said they are being conservative on respiratory season assumptions and expect acceleration in the second half driven by Nutrition recovery, Core Lab Diagnostics growth, and Exact Sciences integration.
Severe negative reset. The report materially damaged the forward outlook and likely forces major downward revisions.
Dividend
Abbott Laboratories pays an annual dividend of $2.52, yielding 2.86%. The dividend payout ratio is 67.23%, indicating a sustainable distribution relative to earnings.
Insider Buying and Selling at Abbott Laboratories
Several insiders have recently purchased shares of Abbott Laboratories. On April 28, 2026, Executive Vice President Mary Moreland bought 5,314 shares at an average price of $94.41. Daniel Starks acquired 10,000 shares on April 27 at $92.65, while on April 24, he purchased an additional 7,105 shares. Other insiders, including Nita Ahuja, Sally Blount, and John Stratton, also made smaller purchases on April 24.
Analysts Set New Price Targets
Several analysts have maintained their buy ratings on Abbott Laboratories. On April 20, 2026, Barclays set a price target of $143. Piper Sandler, Oppenheimer, RBC Capital, Benchmark, Evercore ISI Group, B of A Securities, and Stifel all maintained buy ratings with price targets ranging from $115 to $130 in mid-April. The consensus among 24 analysts is a 'buy', with a mean price target of $116.54.
About Abbott Laboratories
Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois. It develops, manufactures, and sells a wide range of healthcare products, including medical devices, diagnostics, and nutritional products. The company operates in several segments, including Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Led by CEO Mr. Philip P. Boudreau, Abbott employs about 122,000 people worldwide.
Bottom Line
Intech Investment Management's significant increase in Abbott Laboratories shares underscores its growing confidence in the company. Investors closely monitor such institutional moves as they can indicate broader market sentiment. It's important to remember that 13F filings are historical and reflect past holdings, not necessarily current positions.
Get Abbott Laboratories alerts
New 13F filings, insider trades, and analyst moves on $ABT, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.